Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI4TEC)

Drug Name
HTI-1090 Drug Info
Synonyms SHR9146
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMI4TEC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Tryptophan 2,3-dioxygenase (TDO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DN1406131 DMQFX8R Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
2,3-diamino-benzo[b]thiophene derivative 4 DMEDFNC N. A. N. A. Patented [4]
PMID27172114-Compound-30 DMBWLSA N. A. N. A. Patented [4]
2,3-diamino-benzo[b]thiophene derivative 2 DMDYXKT N. A. N. A. Patented [4]
2,3-diamino-benzo[b]thiophene derivative 8 DM5O8K0 N. A. N. A. Patented [4]
2,3-diamino-benzo[b]thiophene derivative 7 DMQVMNJ N. A. N. A. Patented [4]
2,3-diamino-benzo[b]thiophene derivative 6 DMINE6V N. A. N. A. Patented [4]
2,3-diamino-benzo[b]thiophene derivative 5 DM05WXD N. A. N. A. Patented [4]
2,3-diamino-benzo[b]thiophene derivative 1 DMD2KRW N. A. N. A. Patented [4]
2,3-diamino-benzo[b]thiophene derivative 3 DMR7QKL N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Indoleamine 2,3-dioxygenase 1 (IDO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Tryptophan DMIBH7M Depression 6A70-6A7Z Approved [5]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [6]
BMS-986205 DM3MAYQ Melanoma 2C30 Phase 3 [7]
INCB24360 DMIJGT9 Urothelial carcinoma 2C92.0 Phase 3 [8]
NLG8189 DM0798Z Melanoma 2C30 Phase 2/3 [7]
DN1406131 DMQFX8R Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
KHK2455 DMLSUQ8 Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
LY3381916 DMONZ1L Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
PF-06840003 DMOX6EJ Glioma 2A00.0 Phase 1 [9]
NLG802 DMP9J5V Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Indoleamine 2,3-dioxygenase 1 (IDO1) TTZJYKH I23O1_HUMAN Inhibitor [2]
Tryptophan 2,3-dioxygenase (TDO) TTXNCBV T23O_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03208959) A Trial of HTI-1090 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
2 Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
3 ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
4 Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
5 Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
6 Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Incyte. Product Development Pipeline.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)